ARL8B

Across TCGA pan-cancer cohorts, ARL8B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ARL8B data layer compared with 21 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher ARL8B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ARL8B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CESC, COAD, and UCEC are the cancer types where ARL8B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	All	0.616	0.874	.031	6	view →
COAD	OS	Median	All	0.181	0.806	.004	6	view →
UCEC	DFS	Median	All	0.959	0.633	.036	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ARL8B–CESC (OS)

Open the CESC breakdown →